Rachelle Alexis Lim is appointed CEO of MultiSafepay as the Company Aims to Better Serve European SMEs with Innovative Solutions
7.11.2025 14:12:00 CET | Business Wire | Press Release
MultiSafepay, a leading European payment service provider, today announces that Rachelle Alexis Lim has been appointed as the new Chief Executive Officer (CEO) of MultiSafepay.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107657130/en/
Rachelle Alexis Lim is appointed CEO of MultiSafepay.
In her new role, Lim oversees the overall business strategy and operations of MultiSafepay, leading the company to serve a fast-growing client base of SMEs (small and medium-sized enterprises) in Europe, leveraging innovative solutions to drive their inclusive growth. She now also sits on its board of directors, following approval from the Dutch central bank, De Nederlandsche Bank (DNB).
Founder Olaf Geurs, who has served as CEO since establishing MultiSafepay in 1999, will remain Chief Technology Officer (CTO). Geurs will continue to serve on the board of directors, where he and the other existing members will be joined by Lim. In his new capacity, Geurs will continue to drive innovation and oversee the company's technologies.
“Leading MultiSafepay has been an incredible journey for nearly three decades,” said Geurs. “With Rachelle’s exceptional leadership and through our partnership with Antom, we are well positioned for the future. I’ll be working with her closely, while dedicating my focus to our technology, to ensure our innovative spirit continues to drive our success.”
“Rachelle is a fintech veteran, she has been instrumental in establishing Antom’s merchant payment services across European and UK markets. Through strategic business initiatives including a cornerstone collaboration with MultiSafepay, she has significantly expanded the company’s presence in Europe and fuelled strong overall growth,” Geurs further remarked.
Since MultiSafepay began its strategic partnership with Antom, it has processed nearly double the amount of transactions and its merchant base has increased by over a quarter. Its POS and omnichannel offering now accounts for a tenth of its total volume, underscoring the strong market demand for solutions that were once reserved for the largest players.
Lim brings extensive leadership experience to MultiSafepay, from her role of General Manager, EMEA at Antom. Prior to that, as Executive Director at 2C2P, the Filipina leader drove a pivotal expansion by scaling the company's operations and establishing strategic partnerships in her home country and across Asia. Her earlier role as Head of Products for Global Payments Asia Pacific saw her lead successful product launches across POS, eCommerce, and integrated solutions.
"I am thrilled to lead MultiSafepay and build upon the incredible foundation which Olaf has created,” Lim said. “We will focus on empowering SMEs across Europe with the innovative yet simplified payment solutions MultiSafepay is recognised for, which will help drive inclusive growth for businesses of all sizes."
“Under Olaf’s visionary leadership, MultiSafepay has grown into the industry leader it is today. I look forward to scaling the business alongside Olaf in his new role as CTO as we supercharge MultiSafepay’s growth and deliver even greater value to SMEs,” Lim concluded.
Gary Liu, General Manager of Antom, said, “MultiSafepay and Antom have developed a powerful synergy in our mission to provide SMEs with reliable and efficient omnichannel payment solutions. I’m delighted that Rachelle’s been appointed to lead MultiSafepay into its next chapter, her leadership will be instrumental in deepening our partnership and delivering an innovative product suite that empowers the European business community.”
As part of Antom, Ant International’s leading merchant payment and digitisation services provider, MultiSafepay serves over 20,000 businesses across eCommerce, hospitality, retail and entertainment sectors in countries including the Netherlands, Belgium, Italy and Spain. In July 2024, Ant International, headquartered in Singapore, acquired MultiSafepay and has helped accelerate its business, driving innovation for the merchants it serves.
About MultiSafepay
MultiSafepay is a leading European payment service provider, combining decades of expertise with powerful in-house technology to help every business grow faster and compete with confidence, no matter their size or ambition.
By levelling the playing field in payments, we offer European businesses a simple, flexible solution for online, in-person, and unified payments, all through a single platform and integration. With a personal approach to payments, we optimize success rates, reduce complexity, and help your business do more, and earn more.
To learn more, please visit https://www.multisafepay.com/.
About Antom
Ant International's Antom is the leading payment and digitisation services provider for merchants around the world. It offers unified, vertical-specific digital payment solutions to serve businesses of all sizes. Antom supports merchants to integrate over 300 payment methods, enabling them to connect with consumers in more than 200 markets, with the flexibility to accept payments in more than 100 currencies. Beyond payments, it provides digital marketing solutions and merchant digitisation services to help merchant streamline operations and enhance customer engagement.
To learn more, please visit https://www.antom.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251107657130/en/
Contacts
Media inquiries:
pr@ant-intl.com - joshua.way@ant-intl.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom